Showing results (321-330 of 339) with videos related to
Sort By:
Pageof 34
Cytometry. Part B, Clinical Cytometry|February 4, 2021
Validation of inducible basophil biomarkers: Time, temperature and transportationTheodore Kim, Jing Yu, Henry Li, et al.The New England Journal of Medicine|February 23, 2017
Inhibiting Plasma Kallikrein for Hereditary Angioedema ProphylaxisAleena Banerji, Paula Busse, Mustafa Shennak, et al.Lancet (London, England)|February 11, 2023
An investigational oral plasma kallikrein inhibitor for on-demand treatment of hereditary angioedema: a two-part, randomised, double-blind, placebo-controlled, crossover phase 2 trialEmel Aygören-Pürsün, Andrea Zanichelli, Danny M Cohn, et al.EMBO Molecular Medicine|August 3, 2023
Viral anti-inflammatory serpin reduces immuno-coagulopathic pathology in SARS-CoV-2 mouse models of infectionLiqiang Zhang, Yize Henry Li, Karen Kibler, et al.International Journal of Radiation Oncology, Biology, Physics|March 8, 2023
Randomized Phase 2 Placebo-Controlled Trial of Nintedanib for the Treatment of Radiation PneumonitisAndreas Rimner, Zachary R Moore, Stephanie Lobaugh, et al.JTO Clinical and Research Reports|January 2, 2023
A Phase 1 Safety Study of Avelumab Plus Stereotactic Body Radiation Therapy in Malignant Pleural MesotheliomaAndreas Rimner, Prasad S Adusumilli, Michael D Offin, et al.JAMA|November 28, 2018
Effect of Lanadelumab Compared With Placebo on Prevention of Hereditary Angioedema Attacks: A Randomized Clinical TrialAleena Banerji, Marc A Riedl, Jonathan A Bernstein, et al.Nature Communications|September 18, 2021
MAPK-pathway inhibition mediates inflammatory reprogramming and sensitizes tumors to targeted activation of innate immunity sensor RIG-IJohannes Brägelmann, Carina Lorenz, Sven Borchmann, et al.Journal of the American College of Cardiology|July 16, 2025
The Global Syndemic of Modifiable Cardiovascular Risk Factors Projected From 2025 to 2050Bryan Chong, Jayanth Jayabaskaran, Silingga Metta Jauhari, et al.The Journal of Allergy and Clinical Immunology|October 25, 2020
Oral once-daily berotralstat for the prevention of hereditary angioedema attacks: A randomized, double-blind, placebo-controlled phase 3 trialBruce Zuraw, William R Lumry, Douglas T Johnston, et al.Pageof 34